Abstract
Free full text
Modulation of Staphylococcus aureus gene expression during proliferation in platelet concentrates with focus on virulence and platelet functionality
Abstract
Staphylococcus aureus is a well-documented bacterial contaminant in platelet concentrates (PCs), a blood component used to treat patients with platelet deficiencies. This bacterium can evade routine PC culture screening and cause septic transfusion reactions. Here, we investigated the gene expression modulation within the PC niche versus trypticase soy media (TSB) of S. aureus CBS2016-05, a strain isolated from a septic reaction, in comparison to PS/BAC/317/16/W, a strain identified during PC screening. RNA-seq analysis revealed upregulation of the capsule biosynthesis operon (capA-H), surface adhesion factors (sasADF), clumping factor A (clfA), protein A (spa), and anaerobic metabolism genes (pflAB, nrdDG) in CBS2016-05 when grown in PCs versus TSB, implying its enhanced pathogenicity in this milieu, in contrast to the PS/BAC/317/16/W strain. Furthermore, we investigated the impact of S. aureus CBS2016-05 on platelet functionality in spiked PCs versus non-spiked PC units. Flow cytometry analyses revealed a significant decrease in glycoprotein (GP) IIb (CD41) and GPIbα (CD42b) expression, alongside increased P-selectin (CD62P) and phosphatidylserine (annexin V) expression in spiked PCs compared to non-spiked PCs (p = 0.01). Moreover, spiked PCs exhibited a drastic reduction in MitoTrack Red FM and Calcein AM positive platelets (87.3% vs. 29.4%, p = 0.0001 and 95.4% vs. 24.7%, p = 0.0001) in a bacterial cell density manner. These results indicated that S. aureus CBS2016-05 triggers platelet activation and apoptosis, and compromises mitochondrial functionality and platelet viability, in contaminated PCs. Furthermore, this study enhanced our understanding of the effects of platelet-bacteria interactions in the unique PC niche, highlighting S. aureus increased pathogenicity and deleterious effect on platelet functionality in a strain specific manner. Our novel insights serve as a platform to improve PC transfusion safety.
Introduction
Platelet concentrates (PCs) play a critical role in transfusion therapy for patients with thrombocytopenia or impaired platelet functionality. Ensuring the safety of PCs is of utmost importance, considering the millions of PC transfusions conducted annually in the United States alone. PCs are stored in gas-permeable plastic containers under agitation at temperatures of 20–24°C for up to 7 days. These storage conditions make PCs highly vulnerable to proliferation of contaminant bacteria introduced during blood collection [1]. Among the microbiological causes of post-transfusion severe reactions, bacterial contamination of PCs and subsequent transfusion-mediated infections and fatalities pose significant clinical challenges [2].
Staphylococcus aureus, an opportunistic pathogen, is a major reported bacterial contaminant in PCs [1, 3–5]. It enters donated blood during venipuncture at the time of blood collection and can evade detection with automated culture methods, leading to septic transfusion reactions as observed in cases reported in Canada, the US, and the UK [4, 6–8]. In healthy individuals, S. aureus colonizes human anterior nares, with approximately 20–30% of asymptomatic population persistently carrying the bacterium and 20–60% carrying it transiently [9, 10]. Persistent carriers have a higher likelihood of S. aureus colonization on the skin, which can subsequently contaminate PCs if they donate blood.
S. aureus is well-known for causing nosocomial and community-acquired infections and is notorious for its resistance mechanisms against antibiotics and antimicrobial peptides [11]. Formation of surface attached aggregates known as biofilms, and other virulent factors including production of enzymes (e.g., coagulases, proteases) and exotoxins, significantly contribute to S. aureus virulence and persistence [12]. S. aureus isolates exhibit strongly enhanced biofilm formation within the PC environment, and even the biofilm-negative strains turn into biofilm-positive entities [13, 14]. Staphylococcal biofilm matrix usually contains the polysaccharide intercellular adhesin (PIA) encoded by the icaADBC operon [15–17]; however; in PCs, the biofilm matrix of the common PC contaminant Staphylococcus epidermidis consist mainly of proteins and extracellular DNA (eDNA) [13]. Various colonization and intercellular adhesion factors, including microbial surface components recognizing adhesive matrix molecules (MSCRAMMs), are involved in the process of biofilm formation by staphylococci [18]. MSCRAMMs such as fibronectin-binding proteins (FnbA, B), serine-aspartate repeat family proteins (SdrC, SdrD, and SdrE), and clumping factors (ClfA and ClfB), interact with host matrix factors like fibronectin and fibrinogen, while host-derived fibrin also contributes to the biofilm matrix of S. aureus [19, 20]. Biofilms provide protection against the host immune system and confer enhanced resistance to antibiotics and antimicrobial peptides [21]. S. aureus utilizes factors such as ClfA, protein A, and Fnb to interact with platelets, resulting in platelet activation and aggregation [22, 23]. However, neither of these interactions has been explored in the context of PCs or bacteria-mediated transfusion reactions.
Despite the critical role of platelet-bacteria interactions in PC contamination, molecular modifications of S. aureus and impact on platelet functionality remain poorly understood. To address this, we conducted RNA-seq analysis of S. aureus during its interaction with PCs to uncover potential factors linked to immune evasion and missed detection during PC screening. Furthermore, we have recently reported that S. aureus induces metabolic changes in contaminated PCs [24], which was further explored herein with flow cytometry assessing platelet functionality. By integrating RNA-seq analysis and flow cytometry, we aim to comprehensively understand underlying molecular mechanisms of S. aureus-platelet interactions. This exploration will enhance our understanding of PC contamination and guide targeted interventions for safer PC transfusions.
Materials and methods
Platelet concentrates preparation and ethics approval
PCs were manufactured from whole blood donations using the buffy coat pooling method with donor consent obtained in writing and ethical approval granted by the Canadian Blood Services Research Ethical Board (REB 2015.024 AND 2017.033). Blood collection and PC preparation was done by the Canadian Blood Services Blood for Research Facility (Blood4Research, Vancouver, BC, Canada) in agreement with Canadian Blood Services procedures. PC pools were suspended in 100% plasma and shipped to the Canadian Blood Services Microbiology laboratory in Ottawa, Ontario, Canada, where they were screened for bacterial contamination upon arrival with the BACT/ALERT 3D system following standard procedures [25].
Bacterial strains, plasmids, and growth conditions
Two S. aureus strains namely CBS2016-05 and PS/BAC/317/16/W isolated from contaminated PCs in Canada and England, respectively, were selected for this study. CBS2016-05 was isolated post-transfusion after causing a septic reaction in an elderly leukemia patient [7] whereas the PS/BAC/317/16/W strain was detected during PC screening with the automated BACT/ALERT culture system [4]. The S. aureus strains were routinely cultured on Trypticase Soy Agar (TSA) for colony isolation or in Trypticase Soy Broth (TSB) without or with 0.5% glucose (TSBg) and incubated with agitation (20–24°C under agitation for 6 days) or static conditions at 37°C for 24 h. In PCs, the strains were grown aerobically at 20–24°C under agitation for 6 days.
S. aureus RNA isolation, library construction and sequencing
For RNA isolation, the CBS2016-05 and PS/BAC/317/16/W strains were spiked into three independent PC pools and TSB cultures, with an initial concentration of approximately ~4E+06 colony forming units (CFU)/PC unit. The spiked cultures were allowed to grow to the stationary phase at 20–24°C under agitation. Subsequently, the cells were pelleted at 4°C and subjected to total RNA extraction using the miRNeasy Mini Kit (Qiagen), following the manufacturer’s instructions. To eliminate genomic DNA, the RNA samples from three independent biological replicates were treated with TURBO™ DNase AmbionTM (Thermo Fisher Scientific). Furthermore, the RNA samples from spiked PCs underwent an additional treatment using the MICROBEnrich™ kit (Ambion) to remove eukaryotic RNA. RNA sequencing was performed at the Ottawa Hospital Research Institute (OHRI) sequencing facility. Briefly, quality and quantity of the RNA samples were assessed using a Biodrop μLITE and Fragment Analyzer™, revealing an RNA Quality Number (RQN) ranging between 8.7 and 10 for all samples. Subsequently, cDNA libraries were generated using Illumina® Stranded Total RNA Prep, Ligation with Ribo-Zero Plus (Illumina 20040525). Quantification of the libraries was performed with the Qubit Double Stranded DNA HS kit (Thermo Q32854) and ran on the AATI Fragment Analyzer to verify the size distribution. The libraries were normalized, pooled, and diluted as required to achieve acceptable cluster density on the NextSeq 500 sequencer (Illumina SY-414-1001). The library pool then underwent 75 Cycle High Output (Illumina 20024906).
Transcriptome assembly and differential gene expression analyses
Genome sequences of S. aureus CBS2016-05 and PS/BAC/317/16/W have been annotated by our laboratory and uploaded into NCBI [26, 27]. The reference genome sequences were used for transcriptome assembly. Sequence quality control analysis was performed using FastQC and fastp to assess the quality of the reads. Transcript quantification was conducted using Salmon and the reads were aligned to the genome using bowtie2. For differential expression analysis, the transcript quantification data for all 12 samples were imported into R. In the subsequent stages of the analysis, genes encoding rRNA and tRNA were filtered out from the read count matrix, and non-expressed genes (genes with fewer than two replicates with five or more assigned reads) were excluded. DESeq2 was employed to estimate size factors for count scaling based on library size and to calculate dispersion parameters to assess the deviation of expression variance from the mean across the dataset [28]. The DESeq ’rlog()’ function was applied to perform a regularized log transformation of the count values, which were then used in DESeq’s plotPCA() function to generate a PCA plot visualizing the clustering of the replicates. Hierarchical clustering was conducted using the rlog-transformed values to depict similarities between samples. Following the normalization procedure, differentially expressed gene (DEG) analysis was carried out between the PC and TSB conditions for each bacterial strain. The ’lfcShrink()’ function in DESeq2 was employed for this analysis, which calculates the log2 fold change between the conditions while shrinking the value in cases of high uncertainty in the estimated fold change, often arising from low read counts assigned to the gene. The analysis also generated p-values indicating the probability of true differential expression between the conditions, and FDR/q-values were calculated to correct the p-values for multiple testing using the Benjamini-Hochberg approach. The RNA-seq data is accessible through the NCBI Gene Expression Omnibus (GEO) under accession number GSE241582. Gene ontology (GO) functional enrichment analysis of these DEGs was conducted using the ShinyGO enrichment tool.
Validation of RNA-seq data using quantitative reverse transcription PCR (RT-qPCR)
For the validation of RNA-seq data, qRT-qPCR was performed on eleven randomly selected DEGs in triplicate for all the three independent replicates to corroborate expression pattern of RNA-seq data sets. Complementary DNA (cDNA) synthesis was performed with 1 μg of DNase treated total RNA using the iScript cDNA synthesis kit (Bio-Rad) following manufacturer’s instructions and using the following protocol: Priming 5 min at 25°C; Reverse transcription 20 min at 46°C; RT inactivation 1 min at 95°C. The qRT-PCR reaction was carried out in a CFX96 Thermal cycler (Bio-Rad) using iQ SYBR Green super mix (Bio-Rad) as recommended by the manufacturer. Oligonucleotide primers were designed using the PrimerQuest tool at IDT website and efficiency of the primers was determined by the dilution method (100 ng– 0.01 ng) using following protocol: 3 min at 95°C; 40 cycles (10 sec at 95°C; 25 sec at 57°C); 10 sec at 95°C; 5 sec at 65°C. Melt curves were produced to assess the specificity and efficiency of the primers. DNA gyrase A (gyrA) was used as an internal control to normalize the target gene mRNA expression. Fold change in gene expression between TSB and PC samples were calculated using cycle threshold (Ct) values of each gene and the 2–ΔΔCt method [29]. The sequences of the primers used in these procedures are shown in S1 Table.
S. aureus growth curves
Growth curves were performed to compare the growth dynamics of S. aureus CBS2016-05 and PS/BAC/317/16/W at different time intervals in TSB and PCs. The bacterial strains with initial inocula (OD600 = 0.002), which corresponds to ~4E+06 colony forming units (CFU)/mL, were independently inoculated in TSB and PC cultures, and allowed to grow in PC conditions. Samples were withdrawn at the different time points for plating on TSA to determine bacteria concentration (CFU/mL).
Semi-quantitative biofilm assay
S. aureus strains were grown in TSB overnight at 37°C with agitation. An inoculum was added to TSBg and PCs to adjust OD600 to 0.1 and then, 3-mL culture suspensions were dispensed into 6-well polystyrene plates (Falcon, Corning Inc., Durham, NC) and incubated for 24, 48, 72, and 144 h at 37°C or 20–24°C under agitation. After the specified incubation times, supernatants were discarded, and adhered cells (biofilms) were washed three times using 1X PBS and air dried. Biofilms were then stained with Gram crystal violet dye (BD Biosciences, MD, USA) for 30 min and subsequently washed 3 times with 1X PBS. De-staining was done with 80:20 ethanol: acetone solution for 15 min and absorbance was measured at 492 nm in microplate reader. Biofilm quantification was performed from absorbance value subtracting baseline reading obtained with uninoculated TSB and PCs following the recommendations for staphylococci [30].
Flow cytometry analyses
Three buffy coat PC units, each divided into two units were utilized for flow cytometry analyses, from each pair of PCs, one split unit was spiked with S. aureus CBS 2016–05 (at a concentration of 1E+06 CFU/bag) while the second split PC served as control. Platelet counts were determined using the Sysmex pocH-100i™ Automated Haematology Analyser (Sysmex Corporation, Kobe, Hyogo, Japan). The platelet samples were diluted to a concentration of 10–40 x 106 platelets/mL in either phosphate-buffered saline (PBS) or Annexin binding buffer. In the subsequent steps, a range of specific staining procedures were carried out to discern various platelet characteristics. A volume of fifty μL from the diluted platelet samples were stained using platelet-specific Allophycocyanin (APC)-conjugated CD41a (GPIIb) antibody (5 μl) (BD Bioscience), phycoerythrin (PE)- conjugated CD62P (P-selectin) antibody (10 μl) (BD Bioscience) as a marker of platelet activation, and fluorescent dye MitoTrack™ Red FM (ABP Biosciences) (2 μL), employed to demonstrate platelet mitochondrial activity. In another staining, Fluorescein-5-isothiocyanate (FITC) conjugated CD42b (GPIbα) antibody (5 μL) (BD Bioscience) was utilized as another platelet marker, and Alexa 488 conjugated Annexin V (1.5 μL) (Thermo Fisher Scientific) was employed to label phosphatidylserine sites on the platelet membrane surface. The staining reactions were brought to a final volume of 100 μL, adjusted with the appropriate buffer, and subsequently stored in a light-protected environment at room temperature (RT) for a duration of 20 minutes. Finally, 400 μL of PBS or Annexin binding buffer was incorporated into each sample prior to analysis on an Attune acoustic focusing cytometer equipped with 488 and 637 nm lasers (Life Technologies, ThermoFisher Scientific, Waltham, MA, USA). Additionally, separate staining using CD41a-APC was performed, involving a 20-minute incubation at RT in darkness, followed by adjusting the volume to 500 μL and addition of Calcein AM (2 uL) (Thermo Fisher Scientific) and further incubation in darkness at RT for 45 minutes and subsequent analysis on flow cytometer. MitoTrack Red FM and Calcein AM diluted solutions were freshly prepared in PBS and DMSO, respectively.
Statistical analyses
Statistical significance levels were determined using 2way ANOVA followed by the Tukey tests using Prism software and Excel software was used to perform two-tailed T-test. Statistical analysis of the RNA-seq data was done in R. Values were expressed as mean ± SE and a p-value of <0.05 was considered statistically significant.
Results and discussion
In modern medicine, PCs hold immense importance, especially in transfusion medicine and hematology, with millions of PC units transfused globally each year. Ensuring PC safety becomes paramount due to potential risks associated with contamination by bacterial pathogens like S. aureus. This bacterium can evade immune defenses mounted by platelets, survive and proliferate in PCs, with some strains evading routine PC screening causing septic transfusion reactions which may result in fatalities [7, 8, 31, 32]. Herein, we studied molecular modulations of S. aureus and its impact on platelet functionality during PC storage.
Time course growth curve and comparative RNA-seq revealed that S. aureus CBS2016-05 and PS/BAC/317/16/W behave differently in PCs
In this study, we compared the growth dynamics of S. aureus strains CBS2016-05 (missed during PC screening) and PS/BAC/317/16/W (detected during PC screening) in PCs and TSB incubated under PC storage conditions (20–24°C under agitation) until they reached early stationary phase. Results showed that CBS2016-05 strain is a slow growing strain in TSB and reached early stationary phase at 96 hr whereas PS/BAC/317/16/W reached stationary phase at 40 hr. Conversely, in PCs, stationary phase was reached at 144h by both the strains and their growth was significantly slower than their growth in TSB conditions (padj = 0.0002) (Fig 1A and 1B).
These data demonstrate that the PC storage environment is challenging for S. aureus proliferation likely due to low nutrient availability and immune factors present in plasma and released by platelets. Accumulating evidence have substantiated the potent ability of platelets to defend against S. aureus attacks, exhibiting either direct killing of S. aureus or their phagocytosis by macrophages, leading to intracellular elimination [33, 34]. Upon contact with S. aureus, platelets undergo activation, aggregation, or de-granulation, subsequently releasing a repertoire of antimicrobial compounds collectively referred to as platelet microbicidal proteins (PMPs) [35–37]. However, many S. aureus strains survive and proliferate within PCs indicating that S. aureus has the ability to activate immune evasion mechanisms against immune factors [6–8].
Comparative transcriptome profiling performed at early stationary phase unveiled 358 and 315 differentially expressed genes (log2FoldChange ≥2 or ≤-2, p<0.05,) [28] in S. aureus CBS2016-05 and PS/BAC/317/16/W, respectively (S2 Table). Principal component analysis (PCA) of the DEGs revealed samples spiked in TSB tend to cluster together whereas the samples in PCs show more dispersion indicating more variability (Fig 2A and 2B). Dispersion of samples in PCs likely reflect the characteristic variability inherent to each PC donor [38] as not all three PC units cluster together (Fig 2A and 2B). Amongst the DEGs, we found 181 and 133 genes with significant upregulation (≥2-fold) and 178, 181 genes with significant downregulation (≤-2-fold) in CBS2016-05 and PS/BAC/317/16/W strains, respectively (Fig 2C and 2D). Gene ontology (GO) analysis of these DEGs revealed enrichment of amino acid, organic acid, and cellular metabolic processes in both strains, except for pathogenesis, which was enriched solely in the CBS2016-05 strain (S1A and S1B Fig). S. aureus possesses robust metabolic capabilities, enabling it to persist and colonize challenging environments through the production of a diverse array of virulence factors, immune evasion mechanisms, and various proteins and metabolites crucial for its survival. Additionally, S. aureus adeptly employs different carbon and nitrogen sources for its successful colonization within specific niches [39]. Given this, we focused on analyzing key pathways that underpin the survival, persistence, and proliferation of S. aureus in PCs.
Capsule biosynthesis gene expression by S. aureus CBS2016-05 is highly enhanced in PCs
To elucidate the trend of S. aureus gene expression, we compared major S. aureus pathways modulated between CBS2016-05 and PS/BAC/317/16/W in PCs versus TSB (Table 1). A notable observation was the 16-gene operon required for capsule biosynthesis with genes (capABCD) that were strongly upregulated in CBS2016-05 in PCs with 5.8-fold upregulation whereas in PS/BAC/317/16/W, these genes were not differentially expressed, implying enhanced capsule formation in CBS2016-05 when grown in PCs. Genes encoding for saeRS, the two-component system (TCS) which negatively regulates capsule biosynthesis [40], were preferentially repressed in CBS2016-05 (-3-fold) (Table 1).
Table 1
Proteins | Genes | CBS2016-05 log2fold | PS/BAC/317/16/W log2fold | Pathways |
---|---|---|---|---|
accessory gene regulator AgrB | agrB | -2.00 | -1.79 | Agr quorum sensing/ surface proteins |
cyclic lactone autoinducer peptide | agrD | -1.99 | -2.02 | |
GHKL domain-containing protein | agrC | -2.00 | -1.82 | |
response regulator transcription factor | agrA | -2.11 | -1.63 | |
bi-component gamma-hemolysin HlgAB/HlgCB | hlgB | -3.21 | -2.44 | |
bi-component gamma-hemolysin HlgCB subunit C | hlgC | -2.82 | -2.50 | |
bi-component gamma-hemolysin HlgAB subunit A | hlgA | -2.92 | -5.26 | |
delta-hemolysin | hld | -7.55 | -2.19 | |
alpha-hemolysin | hyl | 1.22 | -1.68 | |
phenol-soluble modulin PSM-alpha-1 | PSM-alpha-1 | -11.93 | -7.95 | |
phenol-soluble modulin PSM-alpha-2 | PSM-alpha-2 | -11.48 | ||
phenol-soluble modulin PSM-alpha-3 | PSM-alpha-3 | -9.91 | -9.08 | |
phenol-soluble modulin PSM-alpha-4 | PSM-alpha-4 | -4.63 | ||
beta-class phenol-soluble modulin-1 | psm beta1 | -8.71 | -7.87 | |
beta-class phenol-soluble modulin-2 | psm beta2 | -8.06 | ||
Glu-specific serine endopeptidase | sspA | -5.13 | 2.00 | |
cysteine protease staphopain B | sspB | -4.09 | ||
staphostatin B | sspC | -4.09 | ||
cell-wall-anchored protein | sasF | 1.70 | ||
LPXTG cell wall anchor domain-containing protein | sasD | 2.82 | -3.87 | |
serine-rich repeat glycoprotein adhesin SasA | sasA | 1.96 | ||
fibrinogen-binding adhesin SdrG C-terminal | sdrG | 1.34 | ||
autolysin/adhesin | aaa | -2.45 | 2.79 | |
MSCRAMM family adhesin clumping factor | clfA | 1.55 | -1.39 | |
MSCRAMM family adhesin clumping factor | clfB | 2.24 | 2.58 | |
protein VraX | vraX | 3.02 | Immune evasion | |
staphylococcal protein A | spa | 5.80 | -1.52 | |
myeloperoxidase inhibitor SPIN | spn | -5.94 | -3.22 | |
complement inhibitor SCIN-A | scn | -3.04 | -2.43 | |
extracellular adherence protein Eap/Map | eap | -3.57 | ||
MAP domain-containing protein | map | -2.80 | ||
staphylocoagulase | coa | -3.89 | Other virulence factors | |
von Willebrand factor binding protein Vwb | vwb | 1.41 | ||
YSIRK domain-containing triacylglycerol lipase | lip1 | -2.24 | -5.34 | |
YSIRK domain-containing triacylglycerol lipase | lip2/geh | 2.28 | -1.22 | |
phosphatidylinositol-specific phospholipase C | plc | 2.61 | ||
type 8 capsular polysaccharide synthesis protein | cap8P | 2.46 | 1.55 | Capsule Biosynthesis |
type 8 capsular polysaccharide synthesis protein | cap8O | 4.11 | 1.50 | |
capsular polysaccharide type 5/8 biosynthesis epimerase | capN | 4.35 | 1.80 | |
type 8 capsular polysaccharide synthesis protein | cap8M | 4.52 | 1.84 | |
type 8 capsular polysaccharide synthesis protein | cap8L | 4.70 | 2.04 | |
capsular biosynthesis protein | cap8K | 4.89 | 2.08 | |
O-antigen ligase family protein | cap8J | 4.74 | 2.03 | |
glycosyltransferase | cap8I | 4.94 | 2.13 | |
antibiotic acetyltransferase | cap8H | 5.22 | 1.81 | |
type 8 capsular polysaccharide synthesis protein | cap8G | 5.40 | 1.64 | |
type 8 capsular polysaccharide synthesis protein | cap8F | 5.50 | 1.50 | |
type 8 capsular polysaccharide synthesis protein | cap8E | 5.43 | 1.23 | |
type 8 capsular polysaccharide synthesis protein | cap8D | 5.56 | ||
type 8 capsular polysaccharide synthesis protein | cap8C | 5.83 | ||
type 8 capsular polysaccharide synthesis protein | cap8B | 5.93 | ||
capsular polysaccharide type 5/8 biosynthesis | capA | 5.89 | ||
response regulator transcription factor | saeR | -3.15 | -1.44 | Regulatory proteins |
two-component system sensor histidine kinase SaeS | saeS | -3.33 | -1.31 | |
response regulator transcription factor | kdpE | 2.24 | 1.86 | Potassium transport |
sensor histidine kinase KdpD | kdpD | 2.57 | 2.01 | |
potassium-transporting ATPase subunit A | kdpA | 4.97 | 2.62 | |
potassium-transporting ATPase subunit KdpB | kdpB | 3.77 | 1.38 | |
K(+)-transporting ATPase subunit C | kdpC | 3.82 | 1.21 | |
K(+)-transporting ATPase subunit C | kdpC | 7.06 | ||
K(+)-transporting ATPase subunit B | kdpB | 6.79 | ||
potassium-transporting ATPase subunit A | kdpA | 6.55 | ||
sensor histidine kinase KdpD | kdpD | 2.99 | ||
response regulator transcription factor | kdpE | 2.71 | ||
pyruvate formate lyase-activating protein | pflA | 6.59 | 1.95 | Anaerobic/aerobic metabolism |
formate C-acetyltransferase | pflB | 4.44 | ||
acetolactate synthase AlsS | alsS | 6.89 | 5.73 | |
acetolactate decarboxylase | budA | 6.76 | 5.79 | |
anaerobic ribonucleoside-triphosphate reductase | nrdD | 3.12 | 1.09 | |
anaerobic ribonucleoside-triphosphate reductase activating protein | nrdG | 5.05 | 2.65 | |
class 1b ribonucleoside-diphosphate reductase subunit beta | nrdF | 2.48 | ||
class 1b ribonucleoside-diphosphate reductase subunit alpha | nrdE | 2.38 | ||
class Ib ribonucleoside-diphosphate reductase assembly flavoprotein NrdI | nrdI | 2.32 | ||
threonine ammonia-lyase IlvA | ilvA | -4.94 | 1.22 | Amino Acid metabolism |
3-isopropylmalate dehydratase small subunit | leuD | -5.14 | 1.08 | |
3-isopropylmalate dehydratase large subunit | leuC | -5.18 | ||
3-isopropylmalate dehydrogenase | leuB | -5.38 | ||
2-isopropylmalate synthase | -5.58 | |||
ketol-acid reductoisomerase | ilvC | -5.74 | ||
ACT domain-containing protein | ilvH | -5.59 | 1.87 | |
biosynthetic-type acetolactate synthase large subunit | ilvB | -5.57 | 1.94 | |
dihydroxy-acid dehydratase | ilvD | -4.93 | 2.25 | |
branched-chain amino acid transport system II carrier protein | brnQ | 1.68 | 2.50 | |
betaine-aldehyde dehydrogenase | betB | 6.74 | 3.64 | |
choline dehydrogenase | betA | 3.46 | 2.75 | |
superoxide dismutase | 3.02 | |||
superantigen-like protein SSL14 | SSL14 | 6.66 | Superantigens | |
superantigen-like protein SSL13 | SSL13 | 5.68 | ||
superantigen-like protein SSL12 | SSL12 | 4.75 | ||
superantigen-like protein SSL10 | SSL10 | 1.41 | ||
staphylococcal enterotoxin type H | seh | 2.30 | ||
exotoxin | 3.58 | |||
oleate hydratase | ohyA | 5.55 |
Capsular polysaccharides (CPs) are decorated on the peptidoglycan layer along with wall teichoic acid (WTA) and have a vital function in virulence, impeding phagocytosis as well as equipping bacteria to evade immune defenses thus enabling bacterial persistence [41, 42]. Two types of serotypes of CPs are produced by S. aureus viz. CP 5 and 8 [43, 44] which are known to be involved in invasive diseases. Upregulation of the cap operon by CBS2016-05 in PCs highlights how virulence is triggered by the PC storage challenging environment, which likely contributed to this strain being involved in a septic transfusion reaction [7].
Suppression in expression of agr quorum sensing pathway genes coupled with upregulation of biofilm-related genes
Another important observation from RNA-seq data was the complete repression in transcription of the accessory gene regulator (agr) quorum sensing pathway. Agr is the master regulator of S. aureus virulence and controls the production of numerous virulence factors through agrA, and RNAIII, which positively regulates the production of phenol soluble modulins (PSM) and proteases, and negatively controls the expression of surface adhesins. We observed strong repression of genes encoding for psm-alpha1-4, psm-beta1,2 (up to -11.9-fold) and hld (-7.5-fold) in CBS2016-05 whereas lesser repression of genes psm-alpha1,3 (up to -9-fold); psm-beta1 (-7-fold); and hld (-2.1-fold) in PS/BAC/317/16/W (Table 1). Surface adhesins like clfA, clfB, and sasADF which promote biofilm formation were upregulated (~2-fold) thus implying enhanced biofilm formation in PCs by CBS2016-05 [7, 45]. Increased biofilm formation was observed in PCs compared to TSB as recently demonstrated [14]. Downregulation of agr and psm genes have been previously implicated in enhanced biofilm biosynthesis, colonization, and persistence [46, 47]. The icaBDCA operon which is associated with the formation of PIA-mediated biofilm matrix, did not show significant differential expression. The lack of upregulation in the ica genes, despite other observations pointing towards an increased biofilm presence, can be ascribed to their function as adhesion factors during the initial phases of biofilm formation [48]. Furthermore, our studies have previously highlighted that Staphylococcus species predominantly form protein and eDNA-mediated biofilms in PCs [13, 49].
Differential gene expression of immune evasion factors in PCs
Major immune evasion factors such as myeloperoxidase inhibitor SPIN (spn), complement inhibitor SCIN-A (scn), extracellular adherence protein Eap/Map (eap), and MAP domain-containing protein (map) were significantly downregulated in both strains grown in PCs compared to TSB. In contrast, the gene encoding for staphylococcal protein A (spa) was upregulated in CBS2016-05 (5.8-fold) and downregulated in PS/BAC/317/16/W (-1.5-fold) (Table 1). Protein A has been implicated in immune evasion and sepsis [50–52]. It is known to inhibit the host’s humoral immune response by blocking opsonophagocytosis and inducing apoptosis [53]. Moreover, vraX was upregulated only in CBS2016-05 strain and the VraX protein was recently reported to bind to C1q for the inhibition of classical complement pathway consequently promoting S. aureus survival and pathogenesis [54].
Enriched anaerobic metabolic activity of CBS2016-05 grown in PCs
Unexpectedly, we also observed significant upregulation of genes with important physiological roles in anaerobic metabolism such as pyruvate formate lyase (pflA) and formate acetyltransferase (pflB) (up to 6-fold) which play an important role in the biosynthesis of proteins, DNA, and RNA under anaerobic conditions. These genes exhibit markedly higher expression in biofilm cells compared to planktonic cells [45]. These enzymes contribute to formic acid production, inducing acidification in the biofilm environment. The acidification is detrimental to the host immune response, bolstering S. aureus persistence. It is possible that the presence of S. aureus in PCs might induce localized acidification, but the bacteria possess mechanisms to counter detrimental acidity. Previously, urease genes have been reported to be upregulated in biofilms in acid stress conditions [45, 55], however we observed the entire urease operon ureABCEFGD downregulated (S1 Table). Arginine deiminase pathway genes (arcABCD) and arginine biosynthetic pathway genes (argJBCFGH) exhibited upregulation and these pathways have been reported to facilitate pH homeostasis and biofilm maturation [56]. Anaerobic ribonucleoside reductases nrdDG, pivotal for DNA synthesis and repair, were notably upregulated in CBS2016-05 compared to PS/BAC/317/16/W strain. Remarkably, only PS/BAC/317/16/W displayed upregulation of aerobic ribonucleoside reductases. Genes alsS and budA were more than 5-fold upregulated in both CBS2016-05 and PS/BAC/317/16/W (Table 1). The alsS gene is known to help S. aureus in overcoming nitric oxide (NO) and acid stress, and resistance to antibiotics [57]. Taken together, these findings suggest that CBS2016-05 predominantly adopts a biofilm state characterized by anaerobic metabolism and acidic conditions, as reflected in the formation of small aggregates within PCs as previously reported by Loza et al (2017) [7]. The important implication for this finding is that biofilm formation has been implicated in missed bacterial detection during PC screening [7] and we speculate that growth in small anaerobic niches (biofilm aggregates) may have contributed to missed detection and subsequent transfusion of a PC contaminated with S. aureus CBS2016-05.
Enhanced expression of superantigen genes in CBS2016-05 in comparison to PS/BAC/317/16/W
Staphylococcal superantigen-like (SSL) proteins SSL12, SSL13, SSL14 showed high upregulation in CBS2016-05 (up to-6 fold) and not in PS/BAC/317/16/W and these proteins are involved in immune evasion [58]. Notably, SSL10 showed 1.4-fold upregulation in CBS2016-05 and is known to be involved in inducing necroptosis by binding to the TNFR1 receptor of the human cells as recently reported by Jia et al (2022) [59] (Table 1). Additionally, we also observed upregulation of staphylococcal enterotoxin type H (seh) and an exotoxin with unknown function in the CBS2016-05 strain. SEH is a potent inducer of cytotoxicity in T cells and has the highest affinity in low nanomolar range to bind to MHC class II molecules and has thus potential to cause cytokine storm and consequently toxic shock syndrome [60, 61]. Recently, Chi and Ramirez-Arcos, (2022b) [14] mutated the seg and seh genes, leading to enhanced growth and a significant reduction in biofilm formation in the knockout mutants when compared to the wild type strain. Also, these superantigens could be used as early biomarkers for the detection of superantigen producing S. aureus in PCs considering their strong involvement in septic reactions [62].
Gene expression modulation underlying amino acid metabolism, stress resistance, and niche adaptation
A substantial downregulation (up to 5-fold) of the branched-chain amino acid (BCAA) operon in CBS2016-05 was observed. BCAAs (isoleucine, leucine, and valine) are integral to diverse protein synthesis processes, the generation of branched-chain fatty acids, and the organism’s adaptability to diverse ecological niches [63]. The biosynthesis of BCAAs is intricately regulated in response to the availability of these amino acids in the environment, suggesting a potential enrichment of BCAAs within PCs. Our RNA-seq analysis further divulged the upregulation of betaine-aldehyde dehydrogenase (betB) and choline dehydrogenase (betA), pivotal enzymes driving the synthesis of betaine- an osmoprotectant metabolite crucial for cellular growth and recovery [64]. This enhanced expression underscores the strong resilience of CBS2016-05 strain against osmotic stress, reflecting an adept adaptation mechanism to thrive within challenging PC environment. Additionally, the enhanced expression of superoxide dismutase- a key enzyme orchestrating the neutralization of superoxide radicals arising from host immune responses or aerobic metabolism- further highlights the CBS2016-05 strain capacity to counteract oxidative stress [65].
Interestingly, for the CBS2016-05 strain, an upregulation of up to 7-fold was observed in the potassium transporter operon (kdpABCDE), with two such operons present in this strain. Conversely, in PS/BAC/317/16/W, only a solitary kdpABCDE operon displayed upregulation of up to 2-fold. These high-affinity, K+-specific transport systems play a pivotal role in pH homeostasis through cation transport [66]. Notably, this operon’s upregulation has been documented in HEMRSA-15 (complete operon) and UAS300 (in the form of kdpABC) 24-hr biofilms [67]. It is to be noted that while most S. aureus strains carry a solitary kdp operon, specific strains such as MRSA252, Mu50, and N315 are reported to harbor a second kdp operon [68, 69]. Moreover, the KdpDE two-component system governs the expression of several virulence factors, including the positive regulation of genes related to capsular biosynthesis [70–72]. Our findings resonate with this, given the observed upregulated expression of both Cap biosynthesis and potassium transporter genes (Table 1). Furthermore, in clinical settings, enhanced potassium release is correlated with clotting. It is therefore plausible that PCs inoculated with S. aureus CBS2016-05 accumulated high potassium levels due to the upregulation of the kdpABCDE operon, resulting in aggregate formation, which merits further investigation.
Importantly, PCs contain linoleic acid (18:2) and oleic acid (18:1), both exhibiting antimicrobial properties against Gram-positive pathogens [73, 74]. Increased upregulation of oleate hydratase within CBS2016-05 possibly counteracts this antimicrobial immune response, effectively disarming antimicrobial unsaturated fatty acids and thereby enhancing bacterial survival within the complex milieu of PCs [75, 76].
RT-qPCR validated the RNA-seq data
To validate the robustness of our RNA-seq findings, we conducted qRT-PCR of randomly selected eleven genes. These genes spanned diverse biological functions, encompassing capsule biosynthesis (capA and capB), immune evasion and virulence (spa, clfA and vrax), anaerobic metabolism (nrdG), amino acid metabolism (arcA, glnA and ilvA), regulatory factors (sigB and mgrA). Through qRT-PCR gene expression analysis, the results consistently mirrored the trends observed in RNA-seq analysis (Fig 3), affirming the reliability and accuracy of our experimental outcomes.
S. aureus induces apoptotic modulations in platelets as revealed by flow cytometry
We employed flow cytometry to assess the impact of S. aureus on platelet functionality. Differential expression of platelet functional and activation markers was compared between buffy coat PC units spiked with S. aureus CBS2016-05 and non-spiked units. The percentage of platelets positive for CD62P (P-selectin) expression was significantly increased in spiked units compared to non-spiked units at 48 hr (approximately 24.8% vs. 65.5%, p = 0.005) (Fig 4A and 4B). Notably, CD62P expression demonstrated a general increase after every 24 hr, indicating platelet activation over time during PC storage, with the presence of S. aureus accelerating this process. Additionally, we evaluated the expression of GP IIb and GPIbα (CD41 and CD42b), well-known platelet surface receptors for extracellular matrix molecules like fibrinogen. Spiked PCs exhibited a non-significant decrease in the percentage of GPIIb expression at 48 hr-period (approximately 97.8% vs. 71.4%, p = 0.07), while a significant drop was observed at 144 hr-period (approximately 96.4% vs. 49.2%, p = 0.01). Similarly, GPIbα expression significantly decreased at 48 hr (90.3% vs. 56.9%, p = 0.02) and 144 hr-period (92.6% vs. 28.6%, p = 0.0001) (Fig 4A and 4B). The impact on platelet activation was dependent on a bacterial concentration of 6E+08 CFU/mL and is consistent with our recent observation in single donor apheresis PCs [24]. Furthermore, the percentage of phosphatidylserine+ platelets significantly increased in spiked PCs after 48 hr of storage (3.4% vs. 46.7%, p = 0.02) and further increased at 144 hr (7% vs. 51.6%, p = 0.02), indicating apoptotic-like changes. It is therefore important to note that loss of platelet functionality with low bacterial counts is possible but not detectable in our assays which are dependent on bacterial density.
Considering the role of mitochondria in the maintenance of cellular metabolism, impairment in platelet mitochondrial function is a critical parameter that can be used to evaluate the fate of the platelets. Thus, we used mitochondrial-specific MitoTrack™ Red FM (ABP Biosciences) for evaluating the impact of bacterial contamination on platelet mitochondrial health [77], and we observed a significant decrease in mitochondrial membrane potential in spiked PCs at 48 and 144 hr of storage (87.3% vs. 29.4%, p = 0.0001), providing evidence of membrane depolarization. This finding was further corroborated with a Calcein AM assay, which demonstrated a significant decrease in platelet vitality and metabolic activity at 48 and 144 hr (96.1% vs. 75%, p = 0.0005; 95.4% vs. 24.7%, p = 0.0001) (Fig 4A and 4B). Overall, spiked PCs exhibited features consistent with apoptosis at 48 hr when the S. aureus concentration was 6E+08 CFU/ml, as indicated by increased annexin V expression and decreased MitoTrack Red FM and Calcein AM signals.
Conclusion
Our comparative transcriptomic analysis between S. aureus CBS2016-05 and PS/BAC/317/16/W strains in two milieus, TSB and PCs, has highlighted an important repertoire of virulence factors possibly involved in platelet dysfunction and immune evasion. Specifically, an upregulation of genes encoding for capsule biosynthesis (capA-H), surface adhesion factors (sasADF), clumping factor A (clfA), and protein A (spa) within CBS2016-05 has been unveiled when grown in PCs. Upregulation of these virulence factors might have contributed to the fact that this strain escaped detection during routine PC culture screening and caused a severe transfusion reaction.
Moreover, our investigation into the interplay between S. aureus CBS2016-05 and PCs have demonstrated that this strain stimulates a drastic decline in GPIIb (CD41), GPIbα (CD42b), MitoTrack Red FM and Calcein AM positive platelets, accompanied by heightened P-selectin (CD62P) and phosphatidylserine (annexin V) expression. These changes are reflective of platelet activation and compromised mitochondrial functionality, highlighting that S. aureus can strongly impact platelet behavior and possibly introduce apoptotic behaviors.
Collectively, our findings enhanced our understanding of platelet-bacteria interactions, underscoring the enhanced pathogenicity and new roles for S. aureus capsule on bacterial fitness and survival in harsh environments. Differential gene expression revealed potential mechanisms for missed detection of S. aureus during routine PC screening, such as growth in anaerobic biofilm niches contributing to sampling error. Utilizing platelet-S. aureus interactions as a model system becomes highly relevant, as the consequences of these interactions are likely to play significant roles in shaping infection and host defense. Understanding bacterial modulation in PCs and their effect on platelet function provide important data to propose interventions that safeguard transfusion practices and patient well-being.
Supporting information
S1 Fig
Gene ontology functional enrichment analysis was performed using ShinyGO enrichment tool.Significantly enriched pathways in S. aureus CBS2016-05 and PS/BAC/317/16/W strains presented as Dot plots with a p. adjust threshold cut-off of 0.05. Enrichment significance is indicated by bubble color, while bubble size corresponds to gene count in the term.
(TIF)
S1 Table
List pf primers used for qRT-PCR analysis of randomly selected upregulated and downregulated DEGs for S. aureus CBS2016-05 and PS/BAC/317/16/W strains when grown in PCs vs TSB.(XLSX)
S2 Table
List of DEGs in S. aureus PS/Bac/317/16/W strain spiked PCs vs TSB with log2fold-change ≥ 2 or ≤ -2, p<0.05.(XLSX)
Acknowledgments
We thank the volunteer blood donors and staff at the Blood4Research Facility in Vancouver for whole blood collection and PC manufacturing. The authors would also like to acknowledge the assistance of the Ottawa Bioinformatics Core Facility (uOttawa/OHRI), RRID:SCR_022466. B.Y. held a post-doctoral fellowship from Canadian Blood Services during the development of this study, which was funded by Canadian Blood Services (intramural grant awarded to S. R-A.) and Health Canada. The views expressed herein do not necessarily represent the views of the federal government of Canada.
Funding Statement
The project was funded by Canadian Blood Services (intramural grant awarded to Sandra Ramirez-Arcos) and Health Canada.
Data Availability
The RNA-seq data is accessible through the NCBI Gene Expression Omnibus (GEO) under accession number GSE241582.
References
Decision Letter 0
12 Jun 2024
PONE-D-23-40410Modulation of Staphylococcus aureus gene expression during proliferation in platelet concentrates with focus on virulence and platelet functionalityPLOS ONE
Dear Dr. Yousuf,
Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.
Please submit your revised manuscript by Jul 27 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at gro.solp@enosolp. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.
Please include the following items when submitting your revised manuscript:
A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.
If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.
We look forward to receiving your revised manuscript.
Kind regards,
Keun Seok Seo, Ph.D.
Academic Editor
PLOS ONE
Journal Requirements:
When submitting your revision, we need you to address these additional requirements.
1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at
https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and
2. We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar. If you do not know anyone who can help you do this, you may wish to consider employing a professional scientific editing service.
The American Journal Experts (AJE) (https://www.aje.com/) is one such service that has extensive experience helping authors meet PLOS guidelines and can provide language editing, translation, manuscript formatting, and figure formatting to ensure your manuscript meets our submission guidelines. Please note that having the manuscript copyedited by AJE or any other editing services does not guarantee selection for peer review or acceptance for publication.
Upon resubmission, please provide the following:
● The name of the colleague or the details of the professional service that edited your manuscript
● A copy of your manuscript showing your changes by either highlighting them or using track changes (uploaded as a *supporting information* file)
● A clean copy of the edited manuscript (uploaded as the new *manuscript* file)
3. Thank you for stating the following financial disclosure: "The project was funded by Canadian Blood Services (intramural grant awarded to Sandra Ramirez-Arcos) and Health Canada. "
Please state what role the funders took in the study. If the funders had no role, please state: ""The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.""
If this statement is not correct you must amend it as needed.
Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.
4. Thank you for stating the following in the Acknowledgments Section of your manuscript:"We thank the volunteer blood donors and staff at the Blood4Research Facility in Vancouver for whole blood collection and PC manufacturing. The authors would also like to acknowledge the assistance of the Ottawa Bioinformatics Core Facility (uOttawa/OHRI), RRID:SCR_022466. B.Y. held a post-doctoral fellowship from Canadian Blood Services during the development of this study, which was funded by Canadian Blood Services (intramural grant awarded to S. R-A.) and Health Canada. The views expressed herein do not necessarily represent the views of the federal government of Canada."
We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.
Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: "The project was funded by Canadian Blood Services (intramural grant awarded to Sandra Ramirez-Arcos) and Health Canada. "
Please include your amended statements within your cover letter; we will change the online submission form on your behalf.
5. We note that you have included the phrase “data not shown” in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.
6. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.
[Note: HTML markup is below. Please do not edit.]
Reviewers' comments:
Reviewer's Responses to Questions
Comments to the Author
1. Is the manuscript technically sound, and do the data support the conclusions?
The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.
Reviewer #1: Yes
**********
2. Has the statistical analysis been performed appropriately and rigorously?
Reviewer #1: I Don't Know
**********
3. Have the authors made all data underlying the findings in their manuscript fully available?
The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.
Reviewer #1: Yes
**********
4. Is the manuscript presented in an intelligible fashion and written in standard English?
PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.
Reviewer #1: Yes
**********
5. Review Comments to the Author
Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)
Reviewer #1: The manuscript is presented in an intelligible fashion and written in standard English. A few minor changes are suggested:
- Line 210: It would be interesting to know how platelet counts in the units correlate with flow analysis of activation and apoptosis indicators.
- It is interesting to know the K levels, PH value and external inspection of the units (presence of clots) of the tested units in correlation with the gene expression as you found for example that for the CBS2016-05 strain, an upregulation of up to 7-fold was observed in the potassium transporter operon (kdpABCDE), with two such operons present in this strain (Line 406)
- Please include limitations of this study such as the fact that functionality depends on bacterial density.
- How might this be the source of delayed detection of PC units, which are typically held in blood banks for 5-7 days. What are the likely causes of missing detection of this bacterium during routine PC screening using automated culture systems?
**********
6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.
If you choose “no”, your identity will remain anonymous but your review may still be made public.
Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.
Reviewer #1: Yes: Anwar Rjoop
**********
[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]
While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at gro.solp@serugif. Please note that Supporting Information files do not need this step.
Author response to Decision Letter 0
18 Jun 2024
Response to Reviewer 1 Comments:
The manuscript is presented in an intelligible fashion and written in standard English. A few minor changes are suggested:
- Line 210: It would be interesting to know how platelet counts in the units correlate with flow analysis of activation and apoptosis indicators.
Response: Platelet counts for activation and apoptosis assays were performed with samples containing 10-40 x 10^6 platelets/mL, which are the platelet counts required for optimal performance of these assays.
- It is interesting to know the K levels, PH value and external inspection of the units (presence of clots) of the tested units in correlation with the gene expression as you found for example that for the CBS2016-05 strain, an upregulation of up to 7-fold was observed in the potassium transporter operon (kdpABCDE), with two such operons present in this strain (Line 406)
Response: We thank the Reviewer for this important observation. We did not determine pH or K levels in the tested units and therefore cannot directly correlate the upregulation of the kdp operon with clot formation. However, this could be one of the explanations for the aggregates observed in the inoculated units. We added the potential for this correlation in the discussion of the revised manuscript (lines 420-423).
- Please include limitations of this study such as the fact that functionality depends on bacterial density.
Response: This is an important consideration and we have addressed this in the revised manuscript (lines 467-468).
- How might this be the source of delayed detection of PC units, which are typically held in blood banks for 5-7 days. What are the likely causes of missing detection of this bacterium during routine PC screening using automated culture systems?
Response: Platelet concentrates screening is done at approximately 36 hours post blood collection. Bacterial titers are typically very low (<0.01 CFU/ml) in platelet concentrates and if the isolate is a slow grower or a biofilm former, the titer could be under the limit of the detection of culture methods when sampling is done. We have added a sentence to address this question in the revised manuscript (lines 510 and 511).
Response to EDITOR Comments:
1. Please ensure that your manuscript meets PLOS ONE's style requirements https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and
Response: The manuscript complies with PLOS ONE’ style.
2. We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar
Response: The manuscript has been reviewed for proper language usage, spelling and grammar.
3. Thank you for stating the following financial disclosure: "The project was funded by Canadian Blood Services (intramural grant awarded to Sandra Ramirez-Arcos) and Health Canada. "
Please state what role the funders took in the study. If the funders had no role, please state: ""The funders had no role in study design, data collection and analy sis, decision to publish, or preparation of the manuscript.""
If this statement is not correct you must amend it as needed.
Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.
Response: In cover letter, we have added the statement “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript”.
4. We note that you have included the phrase “data not shown” in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data.
Response: The phrase “data not shown” has been removed from the manuscript as the statement is supported by our recent paper as a reference.
Please review your reference list to ensure that it is complete and correct.
Response: The reference list and citations in the manuscript have been reviewed.
Decision Letter 1
10 Jul 2024
Modulation of Staphylococcus aureus gene expression during proliferation in platelet concentrates with focus on virulence and platelet functionality
PONE-D-23-40410R1
Dear Dr. Yousuf
We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.
Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.
An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at gro.solp@gnillibrohtua.
If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact gro.solp@sserpeno.
Kind regards,
Keun Seok Seo, Ph.D.
Academic Editor
PLOS ONE
Additional Editor Comments (optional):
All comments were appropriately addressed
Reviewers' comments:
Acceptance letter
16 Jul 2024
PONE-D-23-40410R1
PLOS ONE
Dear Dr. Yousuf,
I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.
At this stage, our production department will prepare your paper for publication. This includes ensuring the following:
* All references, tables, and figures are properly cited
* All relevant supporting information is included in the manuscript submission,
* There are no issues that prevent the paper from being properly typeset
If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.
Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact gro.solp@sserpeno.
If we can help with anything else, please email us at gro.solp@eracremotsuc.
Thank you for submitting your work to PLOS ONE and supporting open access.
Kind regards,
PLOS ONE Editorial Office Staff
on behalf of
Dr. Keun Seok Seo
Academic Editor
PLOS ONE
Articles from PLOS ONE are provided here courtesy of PLOS
Citations & impact
This article has not been cited yet.
Impact metrics
Alternative metrics
Discover the attention surrounding your research
https://www.altmetric.com/details/165682643
Data
Data behind the article
This data has been text mined from the article, or deposited into data resources.
GEO - Gene Expression Omnibus
- (1 citation) GEO - GSE241582
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
Proof of concept for detection of staphylococcal enterotoxins in platelet concentrates as a novel safety mitigation strategy.
Vox Sang, 118(7):543-550, 11 May 2023
Cited by: 2 articles | PMID: 37170419
Contamination of platelet concentrates with Staphylococcus aureus induces significant modulations in platelet functionality.
Vox Sang, 117(11):1318-1322, 14 Sep 2022
Cited by: 4 articles | PMID: 36102149
Expression of biofilm-associated genes in Staphylococcus aureus during storage of platelet concentrates.
Transfus Apher Sci, 61(6):103456, 11 May 2022
Cited by: 3 articles | PMID: 35606284
Association of Staphylococcus aureus in platelet concentrates with skin diseases in blood donors: Limitations of cultural bacterial screening.
Transfusion, 62(3):621-632, 19 Jan 2022
Cited by: 2 articles | PMID: 35045189
Funding
Funders who supported this work.